bioMerieux

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Type
Public
HQ
Marcy L'Étoile, FR
Founded
1963
Size (employees)
9,376 (est)
bioMerieux was founded in 1963 and is headquartered in Marcy-l'Étoile, FR

bioMerieux Office Locations

bioMerieux has an office in Marcy-l'Étoile
Marcy-l'Étoile, FR (HQ)
376 Chemin de l'Orme

bioMerieux Financials and Metrics

bioMerieux Financials

bioMerieux's revenue was reported to be €2.1 b in FY, 2016 which is a 7% increase from the previous period.
EUR

Revenue (FY, 2016)

2.1 b

Revenue growth (FY, 2015 - FY, 2016), %

7%

Gross profit (FY, 2016)

1.1 b

Gross profit margin (FY, 2016), %

52%

Net income (FY, 2016)

179.2 m

EBIT (FY, 2016)

282.5 m

Market capitalization (19-Oct-2017)

7.9 b

Closing share price (19-Oct-2017)

69

Cash (31-Dec-2016)

178.6 m

EV

8.2 b
bioMerieux's current market capitalization is €7.9 b.
EURFY, 2014FY, 2015FY, 2016

Revenue

1.7 b2 b2.1 b

Revenue growth, %

16%7%

Cost of goods sold

853.9 m975.4 m1 b

Gross profit

844.5 m989.2 m1.1 b
EURFY, 2014FY, 2015FY, 2016

Cash

119.7 m147.1 m178.6 m

Accounts Receivable

449.3 m445.1 m465.8 m

Inventories

299.2 m355.8 m404.4 m

Current Assets

991.4 m1.1 b1.2 b
EURFY, 2014FY, 2015FY, 2016

Net Income

135.5 m110.3 m179.2 m

Cash From Operating Activities

298.3 m310 m335.6 m

Purchases of PP&E

(158.1 m)(208.2 m)(233 m)

Cash From Investing Activities

(502.7 m)(208 m)(257.2 m)
EURY, 2016

EV/EBIT

29 x

EV/CFO

24.4 x

Revenue/Employee

224.3 k

Debt/Equity

0.3 x

Debt/Assets

0.1 x

Financial Leverage

1.9 x
Show all financial metrics

bioMerieux Operating Metrics

FY, 2015FY, 2016

Patents and Patent Applications

581529

Countries

150

Facilities

19
Show all operating metrics

bioMerieux Market Value History

Traffic Overview of bioMerieux

bioMerieux Online and Social Media Presence

bioMerieux News and Updates

Infection Surveillance Solutions Market Estimated to Exhibit 14.4% CAGR during 2017-2025

Global infection surveillance solution market to register a staggering 14.04% CAGR during the forecast- 2017 to 2025. The US$ 316.67 Mn market is likely to surpass US$ 900 Mn in revenues by 2025-end. Posted via Industry Today. Follow us on Twitter @IndustryToday

bioMerieux Company Life and Culture

You may also be interested in